glp-1 for diabetes type 2 Is the Same as Ozempic? Understanding Key Differences GLP-1 receptor agonism: a transformative

SURMOUNT-4 will address the question of weight regain after stopping the drug: patients who took tirzepatide for 6 months, will be assessed for sustained weight loss one year later (NCT04660643)

This drug is a dual agonist that targets both GLP-1 and GIP receptors, which bolsters its ability to diminish body weight

doi: 10.1111/j.1478-3231.2010.02439.x

[DOI] [PMC free article] [PubMed] [Google Scholar] 11.Raverdy V, Baud G, Pigeyre M, et al

The 12mg dose produced average weight loss of approximately 71.2 lbs (32.3 kg) over 68 weeks, with retatrutide 9mg reducing WOMAC knee pain scores by up to 75.8%

Others prefer semaglutide microdosing because they are more familiar with the drug, or because insurance plans cover semaglutide products more readily than tirzepatide